Bevacizumab (& biosimilars)

DO NOT PRESCRIBE (DNP):

NICE TA242: Colorectal cancer (metastatic) 2nd line. Bevacizumab - not recommended with fluoropyrimidines. (Decision date - February 2012).

NICE TA263: in combination with capecitabine for the first line treatment of metastatic breast cancer. (Negative appraisal). (Decision date - September 2012).
NICE TA284: in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer. (Decision date - July 2013).
NICE TA285: in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer. (Decision date - July 2013).
NICE TA353: for treating relapsed platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. (Terminated appraisal). (Decision date - September 2015).
NICE TA436: for treating EGFR mutation-positive non-small-cell lung cancer. (Terminated appraisal). (Decision date - April 2017).
NICE TA560: treating the first occurrence of platinum-sensitive advanced ovarian cancer. (Terminated appraisal). (Decision date - March 2019)

This drug may be funded through the cancer drug fund - seek advice from the oncologist/haematologist/ NHS England.